The Huanglian Jiedu Micropowder Veterinary Grade API is a spray-dried and jet-milled botanical extraction derived from a four-herb aqueous decoction comprising Coptis chinensis (Rhizoma Coptidis), Scutellaria baicalensis (Radix Scutellariae), Phellodendron amurense (Cortex Phellodendri), and Gardenia jasminoides (Fructus Gardeniae). The material is standardised to total alkaloid content expressed as berberine hydrochloride, with a manufactured specification of 18.0–26.0 wt% total alkaloids (berberine plus palmatine), 8.0–12.0 wt% baicalin, and 3.0–5.0 wt% geniposide determined by HPLC-UV at 265 nm against pharmacopoeial reference substances. Particle-size distribution is controlled by jet milling to three grades: the injectable precursor grade is milled to D90 ≤ 10 μm with laser diffraction per ISO 13320:2020; the solid-dose grade is milled to D90 ≤ 25 μm for content uniformity in tablet matrices; and the premix/feed grade is milled to D90 ≤ 75 μm for bulk-density matching with calcium carbonate carriers. Loss on drying is specified as ≤ 5.0 wt% when measured by halogen drying at 105°C for 15 min. Heavy metal limits align with ICH Q3D Category 3 for oral veterinary products: lead ≤ 20 ppm, arsenic ≤ 10 ppm, cadmium ≤ 2 ppm, and mercury ≤ 1 ppm by ICP-MS. Microbial quality follows Chinese Veterinary Pharmacopoeia 2020 Edition monograph 1105: total aerobic microbial count ≤ 10³ CFU/g, total combined yeasts/moulds ≤ 10² CFU/g, and absence of Escherichia coli in 1 g, absence of Salmonella in 10 g. The four-herb composition is preserved at the extraction stage with herb mass ratios conforming to the classical Huanglian Jiedu Tang formulation as codified in the Chinese Veterinary Pharmacopoeia 2020 Edition. This single API supports seven distinct downstream manufacturing routes: terminally sterilised injectables, lyophilised injectable powders, drinking-water soluble powders for poultry, feed premixes for swine, wet-granulated tablets for companion animals, fluidised-bed granules for top-dressing, and surface-modified dispersible powders for aquaculture immersion or feed coating.

What Limits Sterile Filtration Throughput in Aqueous Huanglian Jiedu Fractions?

The terminal sterilisation route for swine injectable solutions requires the micropowder to be reconstituted in Water for Injection at a concentration of 25.0–50.0 mg/mL extract solids (equivalent to 5.0–13.0 mg/mL total alkaloids expressed as berberine hydrochloride). The dissolution vessel is jacketed and maintained at 60°C ± 2°C for 90–120 min under continuous magnetic stirring at 200 rpm. Alkaloid precipitation at ambient temperature is suppressed by pH adjustment to 5.5–6.5 using 0.1 M citrate buffer and by addition of poloxamer 188 at 0.10–0.20 wt% as a non-ionic solubiliser; published extraction data indicate berberine solubility in water falls below 1.0 mg/mL at 25°C and pH ≥ 7.0, making buffer control a critical quality attribute. The solution is clarified sequentially through a 0.45 μm polyethersulfone pre-filter and a 0.22 μm polyethersulfone sterilising-grade membrane with a filtration area of 0.6 m² per 100 L batch. Filter-loading capacity is constrained by residual polysaccharide fractions originating from Scutellaria baicalensis root mucilage; observed flux decline of 40–60% at 25°C over 60 min of recirculation is managed by pre-treatment with 0.1 wt% activated carbon at 60°C for 30 min, followed by depth filtration through a 0.8 μm polypropylene cartridge. Sterilising filtration is followed by aseptic filling into 10 mL or 20 mL amber borosilicate glass ampoules under EU GMP Annex 1 Grade A laminar airflow with a fill accuracy of ± 1.5% using rotary piston pumps. Terminal steam sterilisation at 121°C for 15 min (F₀ ≥ 8.0 min) is applied to the sealed ampoules; however, process validation data from contract manufacturing records indicate baicalin loss of 7.0–9.0% and geniposide loss of 5.0–6.0% under these conditions. Sterility is confirmed per USP <71> using membrane filtration; bacterial endotoxins are controlled to ≤ 0.50 EU/mL per USP <85>; particulate matter is verified per USP <788> and USP <790> with acceptance limits of ≤ 6000 particles ≥ 10 μm and ≤ 600 particles ≥ 25 μm per container. The terminal product is indicated for intramuscular injection at 0.1–0.2 mL/kg body weight in swine, with a maximum single-dose volume of 10 mL per injection site. In-process sterility assurance is maintained through EU GMP Annex 1 media-fill simulation requiring ≥ 5000 filled units per campaign with zero growth after 14 days incubation at 20–25°C and 30–35°C.

In poultry integrator operations across Shandong, Henan, and Liaoning Province feed mills, the drinking-water route is the primary administration pathway for Huanglian Jiedu micropowder because broiler and layer flocks under high-density housing conditions require mass medication without individual injection constraints. The water-soluble powder grade is manufactured by spray-drying the aqueous extract with maltodextrin DE10 as a carrier at a 1:0.6 extract-to-carrier mass ratio, producing hollow spherical agglomerates with a bulk density of 0.35–0.45 g/cm³ and a moisture content of ≤ 3.0 wt%. The spray dryer operates with inlet air at 180°C ± 5°C and outlet air at 75°C ± 3°C at a feed rate of 35–50 L/h for a 250 kg batch. The resulting powder is blended in a 1000 L V-blender with anhydrous glucose, which functions as both a diluent and a dispersion aid, and sodium citrate buffer at a 1:8:1 mass ratio, resulting in a final alkaloid concentration of 2.0–2.6 wt% berberine hydrochloride equivalent. The administration protocol is 0.5–2.0 g of finished powder per litre of drinking water for 5–7 consecutive days, corresponding to a dose of 10–40 mg total alkaloids per litre. Compliance for this dosage form in the EU market falls under Regulation (EU) 2019/6 Article 106 transitional provisions for traditional herbal veterinary medicinal products, and in China under the Chinese Veterinary Pharmacopoeia 2020 soluble powder monograph. Withdrawal periods are established at 3 days for meat and 0 days for eggs based on residue depletion studies submitted in support of the MRL dossier for berberine. Production equipment must be validated for cleaning residual active markers with an acceptance criterion of ≤ 10 ppm berberine in rinse water by HPLC-UV. The primary packaging is a 100 g, 500 g, or 1 kg triple-layer aluminium foil sachet with a heat-seal strength of ≥ 35 N/15 mm per ISO 527-3:2018 and a water vapour transmission rate of ≤ 0.5 g/m²/24 h at 38°C/90% RH per ISO 15106-2:2005. Field-resolved complaints from integrators centre on sedimentation in header tanks when water hardness exceeds 300 ppm CaCO₃, which is mitigated by pre-dissolving the powder in 1:10 warm water at 30–40°C before dilution into the main drinking line; batch-to-batch particle-size variance of ± 15% D90 was identified as the root cause of residual settling in hard-water conditions.

Carrier Selection and Segregation Mechanisms in Swine Premix Blending

Operationally, the micropowder intended for feed premix incorporation is milled to D90 ≤ 75 μm and conditioned to a bulk density of 0.45–0.55 g/cm³, a specification selected to match the density envelope of the calcium carbonate carrier grade used in Chinese feed premix manufacturing. The premix formulation combines the micropowder with 500-mesh heavy calcium carbonate at a dilution of 1:9 active-to-carrier mass, yielding a working premix containing 1.8–2.6 wt% total alkaloids. The mixing operation is performed in a horizontal ribbon mixer with a working capacity of 2000 kg, trough length-to-width ratio of 2.5:1, and a shaft speed of 25 rpm; mixing time is 15 min with a coefficient of variation of ≤ 5.0% for berberine hydrochloride assay across 10 sampling points as per ISO 6497:2002. Segregation risk is assessed by discharging the premix through a 1.5 m drop height into 20 kg multi-wall paper bags with PE liners; sifting segregation studies indicate berberine concentration variance of ≤ 2.5% RSD between top and bottom strata when the mixture contains 0.5 wt% food-grade soybean oil as a dust-suppression and adhesion agent. The feed-mill inclusion rate is 1.0–2.0 kg of premix per tonne of complete finisher feed, equivalent to 5–10 kg of premix per tonne of creep feed in segregated feeding programs. Regulatory compliance for this route in China requires approval under the Ministry of Agriculture and Rural Affairs Announcement No. 1224/2014 (Feed Additives and Premix Administration) and adherence to ISO 22000:2018 feed safety management with hazard analysis covering mycotoxin co-contamination with an aflatoxin B1 limit of ≤ 20 ppb in the final feed per GB 13078-2017. The premix must demonstrate storage stability of 12 months at 25°C/60% RH with berberine assay at 95–105% of label claim and moisture uptake ≤ 1.5 wt% over the shelf life. In feed-mill production records, the most frequent non-conformance is under-dosing caused by bridge formation in the micro-ingredient hopper when relative humidity exceeds 65%, which is resolved by installing bin vibrators operating at 50 Hz and maintaining the micropowder moisture below 4.0 wt%. The terminal product types include 20 kg paper bags and 1000 kg FIBCs with an inner moisture-barrier PE film of 100 μm thickness.

Because content uniformity in low-dose botanical tablets presents a process challenge distinct from synthetic small-molecule APIs, the micropowder is subject to jet milling at 0.8 MPa compressed-air pressure to achieve D90 ≤ 25 μm, a particle-size target that reduces the median particle size but simultaneously increases electrostatic charge generation during subsequent blending; the charge is neutralised by conditioning at 25°C/50% RH for 24 h before mixing. The tablet formulation consists of 20.0–60.0 wt% micropowder (equivalent to 100–300 mg extract per 500 mg tablet), microcrystalline cellulose PH102 as diluent, croscarmellose sodium 3.0–5.0 wt% as disintegrant, povidone K30 2.0–3.0 wt% as aqueous binder, and magnesium stearate 0.5 wt% as lubricant. The granulation route uses a high-shear granulator with a bowl volume of 300 L operating at impeller speed 150 rpm and chopper speed 1500 rpm for 3 min dry mixing followed by binder addition of 50% v/v ethanol-water at a spray rate of 1.2 kg/min. Wet mass is passed through a 1.2 mm screen and tray-dried at 55°C ± 5°C for 4 h to a final moisture of 2.0–3.0 wt%. Dry granules are lubricated for 5 min and compressed on a rotary tablet press with 36 stations at a compression force of 10.0 ± 2.0 kN, producing 500 mg round flat-faced tablets with a hardness of 60–90 N measured by a diametral crushing tester. Compliance testing follows USP <905> uniformity of dosage units with an acceptance value of ≤ 15.0; USP <701> disintegration requires complete disintegration within 30 min in 900 mL purified water at 37°C ± 0.5°C using a basket apparatus; USP <711> dissolution at 50 rpm paddle in 900 mL of 0.1 M hydrochloric acid requires Q = 75% release at 45 min. ICH Q3D elemental impurity risk assessment is applied with the oral veterinary PDE-based control threshold, and total heavy metal contribution from the botanical extract must be subtracted from the excipient contribution before batch release. Package configuration is a 60 cc white HDPE bottle with a child-resistant polypropylene cap and a cotton coil desiccant; the labelled indication is adjunctive therapy for acute bacterial gastroenteritis in dogs at 10–20 mg/kg total alkaloids per day divided into two daily doses for 3–5 days.

The following matrix summarises the formulation-gradient and particle-size relationships across the first four downstream processing routes, as required for cross-dosage form validation during registration submission.

When Lyophilisation Replaces Terminal Steam Sterilisation for Thermolabile Alkaloid Fractions

The decision to lyophilise rather than terminally autoclave the injectable formulation is driven by differential thermal degradation kinetics between the major quaternary amine alkaloids and the iridoid glycoside geniposide. Accelerated stability studies under forced degradation at 121°C for 30 min (equivalent to double sterilisation) demonstrate berberine hydrochloride loss of 4.0–6.0%, palmatine hydrochloride loss of 3.0–5.0%, baicalin loss of 12.0–15.0%, and geniposide loss of 8.0–10.0%; the baicalin degradation pathway proceeds through flavone ring hydrolysis to baicalein and glucuronic acid, with the aglycone exhibiting 10-fold lower aqueous solubility and subsequent precipitation in the ampoule. The lyophilised powder is prepared by dissolving the micropowder in Water for Injection at 20.0 mg/mL total extract basis, with 5.0 wt% mannitol added as a crystalline cryoprotectant and 0.5 wt% glycine as a buffering bulking agent to prevent pH shift during freeze concentration. The solution is filled at 5.0 mL per 10 mL Type I tubular glass vial under EU GMP Annex 1 conditions and loaded into a shelf freeze dryer with a batch capacity of 2500 vials. The lyophilisation cycle freezes the product to −45°C ± 2°C over 90 min and holds for 120 min; primary drying proceeds at a shelf temperature of −20°C ± 2°C and chamber pressure of 0.10 mbar for 24–28 h until the product temperature reaches −25°C with a Pirani/capacitance pressure differential of ≤ 25%; secondary drying ramps to 25°C over 6 h and holds for 8 h at 0.05 mbar. Final moisture content is verified to ≤ 2.0 wt% by Karl Fischer titration per USP <921>. The lyophilised cake is reconstituted with 10 mL Sterile Water for Injection before intramuscular or intravenous administration to cattle, with a reconstitution time of ≤ 90 s under gentle swirl at room temperature. Sterility is verified per USP <71>, bacterial endotoxins per USP <85> with a limit of ≤ 0.50 EU/mL after reconstitution, and subvisible particulate matter per USP <788> light obscuration at ≤ 6000 particles ≥ 10 μm and ≤ 600 particles ≥ 25 μm per container. Bioequivalence between the lyophilised and solution dosage forms for the veterinary registration dossier is addressed per VICH GL18 guidance using a pharmacokinetic study in healthy cattle with berberine AUC₀–₂₄ as the primary metric; published data for this specific botanical-veterinary configuration is limited, requiring a confirmatory pilot study in 8–12 animals per treatment group. Terminal product presentation is Type I tubular glass vials with bromobutyl rubber stoppers and aluminium flip-off caps, labelled for single-dose use only.

In top-spray fluidised-bed processing, the micropowder is converted into a free-flowing granular intermediate suitable for top-dressing onto swine feed rations at the farm level, where mixer access is absent and uniform distribution must be achieved by hand spreading. The granule formulation consists of 10.0–15.0 wt% micropowder (D90 ≤ 45 μm), 70.0–75.0 wt% lactose monohydrate, 5.0–8.0 wt% microcrystalline cellulose, and 2.0–3.0 wt% povidone K30 as binder; the dry blend is charged into a top-spray fluidised-bed granulator with a 500 L product bowl. Process parameters are established at inlet air temperature 65°C ± 3°C, product temperature 38–42°C, atomising air pressure 2.5 bar, nozzle orifice diameter 0.8 mm, and binder spray rate 15–20 g/min; the binder solution is purified water with povidone K30 pre-dissolved at 5.0 wt%. Granulation proceeds until the optical particle-tracker mass mean diameter reaches 200–250 μm with fines (≤ 75 μm) limited to ≤ 15 wt% to prevent dust generation in the barn environment. The granules are dried in the same fluidised-bed unit at 60°C for 15–20 min until moisture content reaches ≤ 5.0 wt% by halogen drying per the Chinese Veterinary Pharmacopoeia 2020 granule monograph method 0832. The finished granule is packed in 500 g and 1 kg thermoformed PVC/PVDC blister-cavity pouches with an aluminium-foil lid, providing a moisture barrier of ≤ 0.3 g/m²/24 h at 25°C/75% RH. The labelled dosing instruction is 2.0–5.0 g granules per animal per day for nursery pigs or 5.0–10.0 g per animal per day for growing-finishing pigs, sprinkled evenly over the daily feed ration for 5–7 days. Process capability analysis from 30 consecutive commercial batches shows granule D50 repeatability of ± 10% and berberine content uniformity of ± 8% RSD; the principal cause of out-of-specification content was uneven fluidisation at batch loads below 60% of the bowl working capacity, which produced a segregated fines fraction with higher-than-label alkaloid concentration in the final 25% of the drying cycle.

At 35 mS/cm, Alkaloid Redispersion Collapses

Where brackish water conductivity exceeds 15 mS/cm, the aquaculture grade of Huanglian Jiedu micropowder requires stable dispersion across water with electrical conductivity ranging from 0.5 mS/cm (freshwater) to 35 mS/cm (brackish water) and pH between 6.5 and 8.5. The micropowder is jet-milled to D90 ≤ 30 μm and surface-modified with β-cyclodextrin at 5.0 wt% in a planetary mixer at 200 rpm for 30 min; the cyclodextrin forms an inclusion complex with the alkaloid cations, raising the aqueous solubility of berberine from 1.0 mg/mL to 3.0 mg/mL at 25°C and pH 7.0, based on phase-solubility measurements reported in the pharmaceutical literature. The dispersible powder is applied to earthen pond systems at 0.3–1.0 g/m³ of pond water (equal to 0.3–1.0 ppm) by pre-mixing in a 200 L plastic drum at a 1:100 concentrate dilution before broadcasting over the water surface from a boat or aerator-driven circulation zone. For medicated feed application, the micropowder is incorporated into extruded floating pellets at 0.1–0.5 wt% of the dry feed mass; the extrusion process operates at barrel temperature 105–120°C and screw speed 350 rpm with a die temperature of 90°C, which subjects the alkaloids to a thermal residence time of ≤ 40 s, limiting berberine degradation to ≤ 3.0% in post-extrusion HPLC assay. The extruded pellets are coated with 2.0 wt% fish oil and the micropowder using a vacuum coater at −0.08 MPa to achieve uniform surface distribution with a coating loss of ≤ 5.0 wt%. Environmental risk assessment for this route is conducted under VICH GL6 Phase I and Phase II requirements; the predicted environmental concentration in pond sediment is ≤ 0.05 μg/kg dry sediment after 7 days of treatment based on partition coefficient estimates, but published data for alkaloid aquaculture degradation half-lives in tropical pond sediments is limited, requiring site-specific monitoring during the pilot registration phase. The terminal product formats are 500 g vacuum-sealed aluminium pouches for pond treatment and 25 kg paper bags with PE liners for feed-mill incorporation. All packaging bears Chinese Veterinary Pharmacopoeia 2020 labelling requirements including batch number, production date, withdrawal period of 30 days for marketed fish, and storage instruction at ≤ 25°C and ≤ 60% RH.

The complete compliance matrix across all seven downstream dosage forms is tabulated below for registration cross-reference during technical dossier compilation.